PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026

EXPO
Oct.10
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.

Key Points

  • FDA Authorization Gap: A 2Firsts review of FDA records found that some ZYN products displayed at the NACS Show were not on the agency's marketing authorization list.
  • ZYN Product Range: PMI showcased ZYN Ultra in 9 mg and 11 mg strengths and its flagship ZYN range in 1.5 mg, 3 mg, 6 mg and 8 mg strengths.
  • IQOS U.S. Sales: A PMI booth representative told 2Firsts that IQOS is currently sold in Florida, Texas and Mississippi, while IQOS ILUMA remains under FDA review.
  • U.S. Manufacturing Investment: PMI highlighted its American operations, including a new Colorado facility that began commercial production of ZYN nicotine pouches in July 2026.

2Firsts

Las Vegas, October 9, 2026

Philip Morris International (PMI) displayed its U.S. portfolio of nicotine pouches, heated tobacco products and other smokeless tobacco products at the 2026 NACS Show in Las Vegas. The exhibition featured ZYN, IQOS and several established oral tobacco brands. A PMI booth representative told 2Firsts that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.

The two-story PMI U.S. booth featured ZYN and IQOS on the first floor, with the second floor dedicated to the company's U.S. investments and business development.

ZYN Product Range and Retail Displays

The booth featured dedicated displays for ZYN Ultra and the flagship ZYN range.

Exhibition materials presented ZYN Ultra in 9 mg and 11 mg nicotine strengths, alongside ZYN Flagship products in 1.5 mg, 3 mg, 6 mg and 8 mg strengths. PMI promoted ZYN Ultra as featuring a hydro-boosted pouch and a redesigned can. A separate display listed Black Cherry, Peach and Dragonberry under a "New Flavor" heading.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_748076_StzHBOrlAEcQEpE7_1791583079?w=1280&h=960
PMI's ZYN portfolio display, showing ZYN Ultra and flagship products across different nicotine strengths. (Photo: 2Firsts)

PMI also presented a convenience-store retail display featuring ZYN, ZYN Ultra, IQOS devices and HEETS tobacco sticks. The display included product shelving, digital promotional screens and prices shown alongside the products.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_834427_DGMuuZzGf7Jg71mt_1791583104?w=960&h=1280
A retail display at the PMI booth featuring ZYN nicotine pouches, IQOS devices and HEETS tobacco sticks. (Photo: 2Firsts)

Some ZYN Products Displayed at NACS Show Are Not on FDA's Authorized List

According to the U.S. Food and Drug Administration's (FDA) published list of authorized nicotine pouch products, 31 ZYN products had received marketing granted orders (MGOs) as of October 9, 2026.

These include 20 flagship ZYN products in 3 mg and 6 mg strengths, authorized in January 2025, and 11 ZYN Ultra products authorized in August 2026, comprising ten 9 mg variants and one 11 mg variant.

A comparison of the FDA list with PMI's NACS displays shows that some products presented at the booth were not included among those authorized. These include the 1.5 mg and 8 mg strengths of the flagship ZYN range and ZYN Ultra Arctic Mint 11 mg.

PMI identifies Arctic Mint as the commercial name for ZYN Ultra Cool Mint. The FDA's August 2026 authorization includes ZYN Ultra Cool Mint 9 mg, but not its 11 mg variant. ZYN Ultra Smooth 11 mg, sold under the commercial name Signature Smooth, is the only 11 mg ZYN Ultra product on the FDA's authorized list.

PMI stated in August that applications for other 11 mg ZYN Ultra variants remained under FDA scientific review.

The three flavors displayed under the "New Flavor" heading—Black Cherry, Peach and Dragonberry—were also absent from the FDA's published ZYN authorization list.

Separately, in June 2026, the FDA authorized 20 previously marketed ZYN products to carry a specific modified-risk claim. Those modified-risk orders covered the same 20 flagship products previously granted marketing authorization, rather than additional products.

IQOS Sales in Three U.S. States

A PMI booth representative told 2Firsts that IQOS is currently sold in Florida, Texas and Mississippi.

The representative said the IQOS products currently marketed in the United States belong to an earlier generation rather than the newer IQOS ILUMA system, which remains under FDA review.

In an April 2026 announcement, PMI confirmed that the FDA was continuing to review premarket tobacco product applications (PMTAs) for IQOS ILUMA.

The FDA also renewed modified-risk authorizations in April for the IQOS 2.4 and IQOS 3.0 systems and three associated HeatSticks products, permitting specific reduced-exposure claims. These were renewals of existing modified-risk authorizations, rather than new marketing authorizations.

At the NACS booth, 2Firsts observed IQOS devices in multiple colors alongside HEETS packs labeled Blue, Green, Bronze, Red and Amber.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_149618_QWZdfcAwdtvDZ8cD_1791583124?w=1280&h=960
IQOS devices and HEETS tobacco sticks displayed at the PMI U.S. booth. (Photo: 2Firsts)

U.S. Investments and Other Smokeless Tobacco Brands

The booth also displayed General Snus, Timber Wolf and Longhorn products.

The second floor was dedicated to PMI's U.S. investments, while a timeline display traced developments in the company's American business, including regulatory authorizations and corporate milestones.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_315410_06eaE17yr1FdmXxt_1791583163?w=1280&h=960
A timeline at the PMI U.S. booth highlighting milestones in the company's American business. (Photo: 2Firsts)

In July 2026, PMI U.S. announced the opening of its Aurora, Colorado, manufacturing campus, where commercial production of ZYN nicotine pouches began that month. The company said the project represented approximately $1.2 billion in planned capital expenditure between 2024 and 2028, including spending already incurred.

The Aurora facility joins PMI's existing U.S. manufacturing operations in Owensboro, Kentucky, and Wilson, North Carolina.

2Firsts will continue reporting from the NACS Show on tobacco and nicotine products, retail developments and regulatory issues in the U.S. market.

Cover image: The PMI U.S. booth at the 2026 NACS Show in Las Vegas, featuring ZYN branding. (Photo: 2Firsts)


2FIRSTS | Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
2FIRSTS | Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
www.2firsts.com

2FIRSTS | NACS SHOW2026 2FIRSTS Frontline Report
2FIRSTS | NACS SHOW2026 2FIRSTS Frontline Report
2Firsts is the world-leading new tobacco industry media and advisory platform, dedicated to providing global professional readers with exclusive reporting, in-depth perspectives, and visionary insights.
www.2firsts.com


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii-based vaping company Volcano eCigs plans to close all 13 physical retail stores on December 31, 2026, affecting approximately 56 employees. Volcano operates retail, wholesale, proprietary product and online sales businesses and has previously described itself in legislative testimony as Hawaii's largest independent vape retailer and wholesaler. Its operating company, Jocor Enterprises LLC, filed a formal closure notice on November 4, citing changes in the state's regulatory environment. From January 1, 2027, Hawaii will restrict the sale, acquisition and possession of vaping devices and e-liquids not listed in a state product directory, alongside separate restrictions on certain disposable devices. The closure concerns Volcano's physical retail network; the company has not announced the termination of wholesale or online operations.
Market
Nov.09
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23